This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Videos
Infographics
Articles
Case Studies
Webinar
Faculty
Stay up to date

Alirocumab Articles

Articles
Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care
Bhatt DL
Journal:
EuroIntervention

First published: December 2, 2022 DOI: 10.4244/EIJ-E-22-00047
View
Articles
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab
Schwartz G, Szarek M, Zeiher A, et al.
Journal:
J Am Coll Cardiol

First published: October 31, 2022 DOI: 10.1016/j.jacc.2022.09.035
View
Articles
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Hagström E, Steg PG, Szarek M, et al.
Journal:
Circulation

First published: June 30, 2022 DOI: 10.1161/CIRCULATIONAHA.121.057807
View
Articles
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
Landmesser U, McGinniss J, Steg PG, et al.
Journal:
Eur J Prev Cardiol

First published: June 16, 2022 DOI: 10.1093/eurjpc/zwac107
View
Articles
Alirocumab after acute coronary syndrome in patients with a history of heart failure
White HD, Schwartz GG, Szarek M, et al.
Journal:
Eur Heart J

First published: April 21, 2022 DOI: 10.1093/eurheartj/ehab804
View
Articles
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial
Räber L, Ueki Y, Otsuka T, et al.
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5218
View
Articles
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
Ostadal P, Steg PG, Poulouin Y, et al.
Journal:
Lancet Diabetes Endocrinol

First published: April 1, 2022 DOI: 10.1016/S2213-8587(22)00043-2
View

How would you rate this content?

© John Wiley & Sons, Ltd. All rights reserved.
Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.